Hansen has announced the completion of the first robot-assisted uterine fibroid embolization in the USA. Sandeep Rao, interventional radiologist, performed the procedure at Sierra Medical Center in El Paso, Texas, using the Magellan Robotic System
The company has announced that commercial cases were performed at The University Hospital, Leuven, Belgium, where Geert Maleux successfully treated two patients with the EOS device
Medtronic announced on 10 October 2014 the executive team who will lead the combined organisation following the close of its proposed acquisition of Covidien. The new company will be comprised of four major business groups and four geographic regions led by a new Executive Committee. Omar Ishrak will remain as chairman and chief executive officer of the new company, Medtronic plc.
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE study.
Ethicon has announced results of a large, retrospective study that showed the use of the Surgicel family of topical absorbable haemostats was associated with lower costs, reduced product usage, shortened length of hospital stay, and reduced transfusions compared to the use of other adjunctive haemostats. The study was presented at the Society for the Advancement of Blood Management annual meeting in Houston, Texas, USA.
Andre Bouhasin, an interventional cardiologist with West County Heart and Vascular Diagnostics, St Louis, Missouri, USA, used a novel device to remove blood clots and emboli from a protective filter and native arteries to restore blood flow in a patient s leg.
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer endorse radioembolisation, specifically with yttrium-90 (Y90) resin microspheres, as a clinically proven technology to “prolong time to liver tumour progression” in patients who have failed to respond to available chemotherapy options.
The ALN inferior vena cava filter has been available in the European market for over a decade. Following US FDA approval a few centres in the USA have gained extensive experience with this filter. A retrospective study reporting intermediate-term experience from the University of Texas Medical was presented at CIRSE 2014.
BTG has announced that it will begin selling its drug-eluting bead and embolization products, DC Bead and Bead Block, directly to physicians in 11 European countries from 1 April 2015. These products, developed and manufactured by BTG, are currently sold in Europe by the Terumo Corporation under a contract that expires on 31 March 2015.
One-year results from a randomised study comparing fibred platinum coils to vascular plugs for the embolization of pelvic varices in order to treat pelvic congestion syndrome have shown that plugs are as good as coils with regard to safety and efficacy. In addition, plugs also significantly reduce procedure and fluoroscopy time, and radiation dose, the study finds.
The audience in the CIRSE 2014 “Controversies in superficial femoral artery treatment” session failed to endorse two motions pertaining to drug-elution in this anatomical segment in the annual meeting (12–17 September, Glasgow, UK). The first motion was “drug-eluting stents will show better five-year patency rates than percutaneous transluminal angioplasty” and the other was “Drug-eluting balloons in all superficial femoral artery lesions”. While the majority vote went against both motions, leaving the proponents of drug-eluting devices disappointed, experts have questioned whether a motion that was more specific with respect to lesion type and length might have elicited a different voting result.
William T Kuo presented the initial results of the PERFECT registry at CIRSE 2014 (the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe, 12–17 September, Glasgow, UK). He explained that systemic thrombolysis for acute pulmonary embolism carries up to a 20% risk of major bleeding, including a 2–5% risk of haemorrhagic stroke.
A special session at the CIRSE 2014 conference in Glasgow, UK, took a close look at the field of renal denervation as it stands today and concluded that there is still plenty of life and promise in the field. This is not the end of renal denervation but the beginning of proper evaluation, experts said.
Celsion Corporation has announced that the first patient has been enrolled in its pivotal phase III OPTIMA study of ThermoDox in combination with optimised radiofrequency ablation in patients with hepatocellular carcinoma. The first patient was treated at Kyungpook National University Hospital in South Korea.
A study group at the Comprehensive Cancer Centre of Medical University of Vienna and AKH Vienna under the guidance of Maria Sibilia from the Institute for Cancer Research has discovered that tumorigenisis of epidermal growth factor receptor (EGFR) does not, as previously assumed, depend on its presence within the tumour cell, but rather from its activity in the cells adjacent to the tumour.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos